Index RUT
P/E -
EPS (ttm) -4.82
Insider Own 2.09%
Shs Outstand 62.62M
Perf Week -1.74%
Market Cap 6.49B
Forward P/E -
EPS next Y -1.64
Insider Trans -12.11%
Shs Float 61.31M
Perf Month 14.37%
Income -288.29M
PEG -
EPS next Q -1.29
Inst Own 105.10%
Short Float 7.41%
Perf Quarter 18.76%
Sales 282.21M
P/S 22.99
EPS this Y 73.51%
Inst Trans -2.79%
Short Ratio 5.93
Perf Half Y 62.79%
Book/sh 4.96
P/B 20.88
EPS next Y 26.02%
ROA -25.53%
Short Interest 4.54M
Perf Year 89.31%
Cash/sh 10.35
P/C 10.02
EPS next 5Y -
ROE -79.53%
52W Range 43.89 - 111.02
Perf YTD 12.35%
Dividend Est. -
P/FCF -
EPS past 5Y -9.19%
ROI -35.09%
52W High -6.66%
Beta 0.70
Dividend TTM -
Quick Ratio 3.61
Sales past 5Y 220.20%
Gross Margin 89.76%
52W Low 136.11%
ATR (14) 4.00
Dividend Ex-Date -
Current Ratio 3.76
EPS Y/Y TTM 50.87%
Oper. Margin -156.23%
RSI (14) 56.61
Volatility 2.65% 3.95%
Employees 655
Debt/Eq 1.92
Sales Y/Y TTM 37.94%
Profit Margin -102.15%
Recom 1.72
Target Price 119.41
Option/Short Yes / Yes
LT Debt/Eq 1.64
EPS Q/Q 164.84%
Payout -
Rel Volume 0.55
Prev Close 104.26
Sales Surprise 18.82%
EPS Surprise 187.01%
Sales Q/Q 51.87%
Earnings May 02 BMO
Avg Volume 766.01K
Price 103.63
SMA20 1.77%
SMA50 9.44%
SMA200 40.06%
Trades
Volume 422,017
Change -0.60%
Date
Action
Analyst
Rating Change
Price Target Change
May-14-24 Initiated
Stephens
Overweight
$140
May-06-24 Upgrade
Leerink Partners
Underperform → Market Perform
$50 → $97
Oct-27-23 Upgrade
Oppenheimer
Perform → Outperform
$85
Aug-21-23 Reiterated
Needham
Buy
$65 → $66
Jul-31-23 Upgrade
Wells Fargo
Equal Weight → Overweight
$55 → $82
Jun-05-23 Downgrade
SVB Securities
Market Perform → Underperform
$48 → $43
Jan-03-23 Upgrade
Wells Fargo
Underweight → Equal Weight
$41
Dec-14-22 Initiated
Needham
Buy
$60
Nov-02-22 Downgrade
Oppenheimer
Outperform → Perform
Sep-14-22 Initiated
Berenberg
Buy
$90
Jul-08-22 Initiated
Oppenheimer
Outperform
$80
Jun-27-22 Initiated
Wells Fargo
Underweight
$40
Jun-10-22 Downgrade
Citigroup
Neutral → Sell
$68 → $41
Jun-01-22 Upgrade
Jefferies
Hold → Buy
$88 → $78
Mar-01-22 Initiated
Citigroup
Neutral
$71
Feb-17-22 Downgrade
SVB Leerink
Outperform → Mkt Perform
$82
Jan-25-22 Upgrade
Stifel
Hold → Buy
$120 → $95
Nov-19-21 Resumed
Morgan Stanley
Equal-Weight
$111
Sep-30-21 Resumed
Stifel
Hold
$105
Jun-04-21 Resumed
Robert W. Baird
Outperform
$119
Show Previous Ratings
May-14-24 07:50AM
May-06-24 05:32PM
04:01PM
11:45AM
07:05AM
10:03AM
Loading…
May-03-24 10:03AM
09:51AM
03:05AM
May-02-24 09:24PM
(Thomson Reuters StreetEvents) +12.80%
11:56AM
10:56AM
10:16AM
08:36AM
08:10AM
07:11AM
(Associated Press Finance)
07:00AM
Loading…
07:00AM
Apr-25-24 10:01AM
Apr-18-24 08:00AM
Apr-11-24 08:00AM
Apr-04-24 04:01PM
Mar-28-24 08:13AM
Mar-17-24 08:50AM
Mar-15-24 07:00PM
Mar-06-24 04:01PM
11:53AM
(Thomson Reuters StreetEvents)
Feb-23-24 08:00AM
Feb-16-24 03:30PM
09:37AM
05:47AM
Feb-15-24 10:50PM
(Thomson Reuters StreetEvents) +14.02%
10:55AM
Loading…
10:55AM
(Investor's Business Daily)
08:25AM
07:43AM
07:26AM
(Associated Press Finance)
07:00AM
(Investor's Business Daily)
07:00AM
Feb-12-24 09:16AM
Feb-08-24 10:00AM
Feb-05-24 04:01PM
Feb-01-24 08:00AM
Jan-16-24 12:00PM
11:51AM
Jan-09-24 01:51PM
Jan-08-24 08:00AM
Jan-05-24 04:01PM
Dec-18-23 08:00AM
Dec-14-23 11:05AM
Dec-12-23 08:05AM
Dec-10-23 11:59AM
Dec-09-23 12:30PM
Dec-04-23 04:01PM
Nov-28-23 08:00AM
Nov-14-23 05:05PM
Nov-13-23 04:29PM
Nov-10-23 08:00AM
Nov-04-23 03:02AM
Nov-03-23 04:01PM
Oct-31-23 09:55AM
09:40AM
03:48AM
Oct-30-23 03:46PM
Oct-28-23 01:49PM
Oct-27-23 10:01AM
07:27AM
Oct-26-23 11:42PM
(Thomson Reuters StreetEvents) +25.61%
05:47PM
09:30AM
08:52AM
08:15AM
07:09AM
(Associated Press Finance)
07:00AM
Oct-25-23 10:15AM
Oct-23-23 08:30AM
Oct-20-23 10:00AM
Oct-19-23 10:01AM
Oct-12-23 08:00AM
Oct-06-23 03:00AM
Oct-05-23 04:01PM
Sep-29-23 11:01PM
Sep-08-23 11:30AM
Sep-07-23 11:30AM
Sep-05-23 04:01PM
Sep-01-23 11:31AM
Aug-04-23 04:16PM
Aug-02-23 01:00PM
12:42PM
09:30AM
08:25AM
07:14AM
07:00AM
Jul-19-23 08:00AM
Jul-14-23 11:53AM
Jul-05-23 04:30PM
Jun-30-23 08:56AM
06:26AM
Jun-12-23 09:30AM
Jun-09-23 09:22AM
Jun-05-23 05:00PM
Jun-04-23 08:45AM
Jun-03-23 09:00AM
Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Hurley Ariel PRINCIPAL ACCOUNTING OFFICER May 15 '24 Option Exercise 37.69 5,856 220,736 20,769 May 17 04:05 PM Hurley Ariel PRINCIPAL ACCOUNTING OFFICER May 15 '24 Sale 106.96 5,856 626,379 14,913 May 17 04:05 PM Landsittel Michael CHIEF FINANCIAL OFFICER May 15 '24 Sale 106.95 3,850 411,772 71,617 May 17 04:05 PM Landsittel Michael CHIEF FINANCIAL OFFICER May 08 '24 Option Exercise 2.32 28,181 65,297 75,467 May 10 04:05 PM Landsittel Michael CHIEF FINANCIAL OFFICER May 02 '24 Option Exercise 36.05 10,000 360,500 57,286 May 06 05:26 PM Hurley Ariel PRINCIPAL ACCOUNTING OFFICER May 02 '24 Option Exercise 54.13 1,834 99,274 16,747 May 06 05:19 PM Landsittel Michael CHIEF FINANCIAL OFFICER May 02 '24 Sale 105.00 10,000 1,050,000 47,286 May 06 05:26 PM Hurley Ariel PRINCIPAL ACCOUNTING OFFICER May 02 '24 Sale 103.88 1,834 190,516 14,913 May 06 05:19 PM Landsittel Michael CHIEF FINANCIAL OFFICER Mar 28 '24 Option Exercise 36.05 5,000 180,250 52,286 Apr 01 04:34 PM Landsittel Michael CHIEF FINANCIAL OFFICER Mar 28 '24 Sale 95.00 5,000 475,000 47,286 Apr 01 04:34 PM Albers Jeffrey W. Director Mar 20 '24 Option Exercise 7.11 25,073 178,287 201,123 Mar 22 05:50 PM Albers Jeffrey W. Director Mar 20 '24 Sale 87.28 25,073 2,188,264 176,050 Mar 22 05:50 PM Landsittel Michael CHIEF FINANCIAL OFFICER Mar 15 '24 Option Exercise 36.05 5,000 180,250 61,020 Mar 19 05:11 PM Hurley Ariel PRINCIPAL ACCOUNTING OFFICER Mar 15 '24 Option Exercise 15.01 1,600 24,016 18,662 Mar 19 04:48 PM Landsittel Michael CHIEF FINANCIAL OFFICER Mar 15 '24 Sale 87.78 13,734 1,205,606 47,286 Mar 19 05:11 PM Hurley Ariel PRINCIPAL ACCOUNTING OFFICER Mar 15 '24 Sale 87.76 4,549 399,213 14,913 Mar 19 04:48 PM Lee Philina CHIEF COMMERCIAL OFFICER Mar 13 '24 Option Exercise 13.15 1,747 22,975 42,752 Mar 15 04:47 PM Lee Philina CHIEF COMMERCIAL OFFICER Mar 13 '24 Sale 90.40 8,023 725,277 34,729 Mar 15 04:47 PM Haviland Kate CHIEF EXECUTIVE OFFICER Mar 07 '24 Sale 90.69 12,464 1,130,360 153,177 Mar 11 06:27 PM Albers Jeffrey W. Director Mar 07 '24 Sale 90.69 11,033 1,000,583 165,017 Mar 26 09:11 PM Rossi Christina CHIEF OPERATING OFFICER Mar 07 '24 Sale 90.69 6,070 550,488 64,306 Mar 11 06:21 PM McCain Tracey L EVP AND CHIEF LEGAL OFFICER Mar 07 '24 Sale 90.69 5,194 471,044 60,498 Mar 11 06:18 PM Durso-Bumpus Debra CHIEF PEOPLE OFFICER Mar 07 '24 Sale 90.69 5,093 461,884 57,585 Mar 11 06:28 PM Landsittel Michael CHIEF FINANCIAL OFFICER Mar 07 '24 Sale 90.69 5,003 453,722 56,020 Mar 11 06:23 PM Namouni Fouad PRESIDENT, R & D Mar 07 '24 Sale 90.69 4,377 396,950 72,703 Mar 11 06:20 PM Hewes L. Becker CHIEF MEDICAL OFFICER Mar 07 '24 Sale 90.69 3,097 280,867 46,281 Mar 11 06:29 PM Lee Philina CHIEF COMMERCIAL OFFICER Mar 07 '24 Sale 90.69 2,934 266,084 41,005 Mar 11 06:26 PM Murray Christopher K. CHIEF TECHNICAL OPERATIONS Mar 07 '24 Sale 90.69 2,521 228,629 33,853 Mar 11 06:24 PM Carter Percy H. CHIEF SCIENTIFIC OFFICER Mar 07 '24 Sale 90.69 2,286 207,317 48,331 Mar 11 06:19 PM Hurley Ariel PRINCIPAL ACCOUNTING OFFICER Mar 07 '24 Sale 90.69 1,462 132,589 17,862 Mar 11 06:15 PM Murray Christopher K. CHIEF TECHNICAL OPERATIONS Mar 04 '24 Sale 93.65 621 58,157 36,374 Mar 06 10:41 AM Murray Christopher K. CHIEF TECHNICAL OPERATIONS Feb 28 '24 Option Exercise 54.13 5,000 270,650 29,495 Mar 01 03:06 PM Murray Christopher K. CHIEF TECHNICAL OPERATIONS Feb 28 '24 Sale 100.00 5,000 500,000 24,495 Mar 01 03:06 PM Albers Jeffrey W. Director Jan 25 '24 Option Exercise 7.13 25,000 178,150 201,050 Jan 29 06:13 PM Albers Jeffrey W. Director Jan 25 '24 Sale 81.91 25,000 2,047,800 176,050 Jan 29 06:13 PM Hurley Ariel PRINCIPAL ACCOUNTING OFFICER Dec 22 '23 Option Exercise 8.80 714 6,283 15,038 Dec 26 04:24 PM Hurley Ariel PRINCIPAL ACCOUNTING OFFICER Dec 22 '23 Sale 90.00 714 64,260 14,324 Dec 26 04:24 PM Hurley Ariel PRINCIPAL ACCOUNTING OFFICER Dec 15 '23 Option Exercise 1.87 3,654 6,833 16,411 Dec 19 04:05 PM Hurley Ariel PRINCIPAL ACCOUNTING OFFICER Dec 15 '23 Sale 84.35 3,914 330,146 14,324 Dec 19 04:05 PM Lee Philina CHIEF COMMERCIAL OFFICER Dec 13 '23 Option Exercise 1.87 261 488 31,439 Feb 14 06:54 PM Albers Jeffrey W. Director Dec 11 '23 Option Exercise 36.05 5,000 180,250 181,050 Dec 13 03:56 PM Albers Jeffrey W. Director Dec 11 '23 Sale 79.07 5,000 395,350 176,050 Dec 13 03:56 PM Murray Christopher K. CHIEF TECHNICAL OPERATIONS Dec 07 '23 Option Exercise 54.13 5,000 270,650 29,495 Dec 11 05:11 PM Murray Christopher K. CHIEF TECHNICAL OPERATIONS Dec 07 '23 Sale 75.00 5,000 375,000 24,495 Dec 11 05:11 PM Murray Christopher K. CHIEF TECHNICAL OPERATIONS Dec 04 '23 Sale 71.43 600 42,858 24,495 Dec 06 08:45 PM Albers Jeffrey W. Director Nov 30 '23 Option Exercise 36.05 5,000 180,250 181,050 Dec 04 04:02 PM Albers Jeffrey W. Director Nov 30 '23 Sale 70.55 5,000 352,750 176,050 Dec 04 04:02 PM Albers Jeffrey W. Director Nov 24 '23 Option Exercise 1.87 15,000 28,050 191,050 Nov 28 04:05 PM Albers Jeffrey W. Director Nov 24 '23 Sale 67.51 15,000 1,012,690 176,050 Nov 28 04:05 PM Albers Jeffrey W. Director Nov 03 '23 Option Exercise 36.05 1,485 53,534 177,535 Nov 03 05:07 PM Albers Jeffrey W. Director Nov 03 '23 Sale 60.13 1,485 89,293 176,050 Nov 03 05:07 PM Albers Jeffrey W. Director Nov 02 '23 Option Exercise 36.05 4,634 167,056 180,684 Nov 03 05:07 PM Albers Jeffrey W. Director Nov 02 '23 Sale 60.37 4,634 279,749 176,050 Nov 03 05:07 PM Albers Jeffrey W. Director Nov 01 '23 Option Exercise 36.05 3,881 139,910 179,931 Nov 03 05:07 PM Albers Jeffrey W. Director Nov 01 '23 Sale 60.02 3,881 232,938 176,050 Nov 03 05:07 PM Murray Christopher K. CHIEF TECHNICAL OPERATIONS Oct 26 '23 Sale 56.40 600 33,840 25,095 Oct 30 02:01 PM Namouni Fouad PRESIDENT, R & D Oct 04 '23 Sale 48.06 3,769 181,138 62,080 Oct 05 10:47 AM Albers Jeffrey W. Director Sep 28 '23 Option Exercise 1.87 6,898 12,899 182,948 Sep 29 02:36 PM Albers Jeffrey W. Director Sep 28 '23 Sale 50.17 6,898 346,073 176,050 Sep 29 02:36 PM Albers Jeffrey W. Director Sep 27 '23 Option Exercise 1.87 18,102 33,851 194,152 Sep 29 02:36 PM Albers Jeffrey W. Director Sep 27 '23 Sale 49.61 18,102 897,957 176,050 Sep 29 02:36 PM Albers Jeffrey W. Director Aug 25 '23 Option Exercise 1.87 10,000 18,700 186,050 Aug 28 06:23 PM Albers Jeffrey W. Director Aug 25 '23 Sale 50.16 10,000 501,600 176,050 Aug 28 06:23 PM Albers Jeffrey W. Director Aug 24 '23 Option Exercise 1.87 15,000 28,050 191,050 Aug 28 06:23 PM Albers Jeffrey W. Director Aug 24 '23 Sale 49.57 15,000 743,550 176,050 Aug 28 06:23 PM Carter Percy H. CHIEF SCIENTIFIC OFFICER Jun 05 '23 Sale 52.06 2,307 120,102 38,117 Jun 07 07:52 PM Hewes L. Becker CHIEF MEDICAL OFFICER Jun 05 '23 Sale 52.05 1,404 73,078 36,878 Jun 07 07:48 PM
Index RUT
P/E -
EPS (ttm) -2.50
Insider Own 11.07%
Shs Outstand 55.59M
Perf Week 0.66%
Market Cap 2.17B
Forward P/E -
EPS next Y -3.09
Insider Trans -11.47%
Shs Float 54.57M
Perf Month 2.82%
Income -154.59M
PEG -
EPS next Q -0.68
Inst Own 101.26%
Short Float 18.16%
Perf Quarter -8.66%
Sales 79.41M
P/S 27.29
EPS this Y -12.16%
Inst Trans 3.66%
Short Ratio 16.65
Perf Half Y 81.78%
Book/sh 11.59
P/B 3.05
EPS next Y -9.33%
ROA -20.86%
Short Interest 9.91M
Perf Year 19.12%
Cash/sh 8.48
P/C 4.16
EPS next 5Y 1.90%
ROE -26.35%
52W Range 9.60 - 45.31
Perf YTD 38.73%
Dividend Est. -
P/FCF -
EPS past 5Y -39.18%
ROI -19.61%
52W High -22.05%
Beta 2.29
Dividend TTM -
Quick Ratio 9.57
Sales past 5Y 241.22%
Gross Margin 94.76%
52W Low 267.92%
ATR (14) 1.80
Dividend Ex-Date -
Current Ratio 9.57
EPS Y/Y TTM 12.88%
Oper. Margin -217.99%
RSI (14) 45.44
Volatility 4.14% 5.01%
Employees 187
Debt/Eq 0.12
Sales Y/Y TTM 70.16%
Profit Margin -194.67%
Recom 1.71
Target Price 50.80
Option/Short Yes / Yes
LT Debt/Eq 0.11
EPS Q/Q 2.46%
Payout -
Rel Volume 0.67
Prev Close 36.01
Sales Surprise -27.75%
EPS Surprise 4.25%
Sales Q/Q 8.67%
Earnings May 02 BMO
Avg Volume 595.12K
Price 35.32
SMA20 -2.37%
SMA50 -5.29%
SMA200 31.75%
Trades
Volume 401,208
Change -1.92%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-22-24 Initiated
Oppenheimer
Outperform
$53
Feb-15-24 Initiated
Wolfe Research
Peer Perform
Jan-04-24 Upgrade
JP Morgan
Neutral → Overweight
Jan-03-24 Downgrade
BofA Securities
Buy → Neutral
$45 → $30
Dec-19-23 Downgrade
Wells Fargo
Overweight → Equal Weight
$26
Jun-30-23 Initiated
Truist
Buy
$50
May-05-23 Upgrade
Raymond James
Mkt Perform → Outperform
Dec-06-22 Downgrade
Credit Suisse
Outperform → Neutral
$47 → $32
Nov-08-22 Initiated
Raymond James
Mkt Perform
Aug-15-22 Initiated
Jefferies
Buy
$40
Aug-03-22 Initiated
Goldman
Buy
$40
Jul-20-22 Initiated
SVB Leerink
Mkt Perform
$26
Apr-28-22 Initiated
Credit Suisse
Outperform
$63
Mar-10-22 Initiated
JP Morgan
Neutral
$44
Feb-10-22 Initiated
Wells Fargo
Overweight
$62
Sep-30-21 Initiated
Stifel
Buy
$80
Sep-30-21 Initiated
B. Riley Securities
Neutral
$67
Sep-10-21 Downgrade
BofA Securities
Buy → Neutral
$65 → $80
May-21-21 Initiated
UBS
Buy
$80
Apr-14-21 Initiated
Berenberg
Buy
Show Previous Ratings
May-14-24 10:00AM
May-08-24 07:00AM
May-03-24 12:23PM
09:57AM
09:55AM
08:44AM
Loading…
08:44AM
03:19AM
May-02-24 12:18PM
11:57AM
07:00AM
Apr-25-24 10:02AM
09:20AM
07:00AM
Apr-08-24 07:00AM
Mar-08-24 10:00AM
11:27PM
Loading…
Mar-04-24 11:27PM
Feb-28-24 07:00AM
Feb-23-24 11:59AM
Feb-22-24 11:24PM
(Thomson Reuters StreetEvents)
07:35AM
07:00AM
Feb-21-24 11:52PM
Feb-15-24 10:00AM
07:00AM
Feb-10-24 02:56AM
Jan-31-24 07:00AM
Jan-24-24 12:20AM
Jan-17-24 08:00AM
Jan-09-24 09:17AM
09:15AM
04:03PM
Loading…
Jan-05-24 04:03PM
(Investor's Business Daily)
06:00AM
Jan-04-24 04:01PM
07:00AM
Jan-02-24 07:00AM
Dec-22-23 10:45AM
Dec-18-23 02:58PM
Dec-13-23 07:00AM
Dec-10-23 09:00PM
Dec-08-23 11:13AM
Dec-07-23 07:00AM
Nov-13-23 11:00AM
Nov-07-23 09:05AM
Nov-05-23 02:38PM
Nov-02-23 09:00AM
08:43AM
07:00AM
Nov-01-23 07:00AM
Oct-27-23 07:00AM
Oct-26-23 10:02AM
07:00AM
Oct-19-23 09:35AM
Oct-18-23 09:35AM
Oct-16-23 07:00AM
Oct-04-23 06:23AM
Oct-03-23 04:48PM
Sep-18-23 07:00AM
Aug-28-23 07:00AM
Aug-03-23 08:25AM
07:00AM
Jul-28-23 03:57PM
Jul-27-23 07:00AM
Jul-09-23 09:09AM
Jun-22-23 08:30AM
Jun-14-23 02:30AM
Jun-09-23 06:00PM
03:00AM
Jun-01-23 07:00AM
May-29-23 12:24PM
May-22-23 07:00AM
May-19-23 07:00AM
May-18-23 07:00AM
May-14-23 02:57PM
May-09-23 03:15PM
May-04-23 08:25AM
07:00AM
Apr-19-23 11:11AM
Apr-11-23 07:00AM
Apr-09-23 01:19PM
Mar-09-23 03:00PM
Mar-03-23 11:40AM
Mar-01-23 07:00AM
Feb-24-23 02:53AM
(Thomson Reuters StreetEvents) -5.13%
Feb-23-23 08:25AM
07:00AM
Feb-01-23 07:00AM
Jan-31-23 08:00AM
Jan-30-23 07:26AM
Jan-23-23 04:14AM
Jan-17-23 06:27AM
Jan-10-23 07:00AM
Jan-09-23 12:00PM
Jan-04-23 07:00AM
Jan-03-23 07:00AM
Dec-21-22 04:57PM
Dec-20-22 10:33AM
Dec-15-22 10:27AM
Dec-14-22 04:09PM
(Investor's Business Daily) +14.58%
01:44PM
10:00AM
Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Booth Bruce Director Mar 15 '24 Sale 40.46 71,764 2,903,336 806,697 Mar 15 07:23 PM Booth Bruce Director Mar 14 '24 Sale 39.98 55,779 2,229,927 819,151 Mar 15 07:23 PM Booth Bruce Director Mar 13 '24 Sale 42.23 139,255 5,880,415 828,830 Mar 13 07:52 PM Atlas Venture Fund X, L.P. 10% Owner Mar 13 '24 Sale 42.23 115,090 4,859,993 4,676,075 Mar 13 07:53 PM Atlas Venture Fund X, L.P. 10% Owner Mar 13 '24 Sale 42.23 24,165 1,020,422 828,830 Mar 13 07:53 PM Booth Bruce Director Mar 12 '24 Sale 41.98 162,918 6,838,813 852,995 Mar 13 07:52 PM Atlas Venture Fund X, L.P. 10% Owner Mar 12 '24 Sale 41.98 134,647 5,652,072 4,791,165 Mar 13 07:53 PM Atlas Venture Fund X, L.P. 10% Owner Mar 12 '24 Sale 41.98 28,271 1,186,741 852,995 Mar 13 07:53 PM Booth Bruce Director Mar 11 '24 Sale 42.85 51,184 2,193,148 881,266 Mar 13 07:52 PM Atlas Venture Fund X, L.P. 10% Owner Mar 11 '24 Sale 42.85 42,302 1,812,586 4,925,812 Mar 13 07:53 PM Atlas Venture Fund X, L.P. 10% Owner Mar 11 '24 Sale 42.85 8,882 380,562 881,266 Mar 13 07:53 PM Jacobs Bruce N. Chief Financial Officer Mar 04 '24 Sale 41.86 3,934 164,664 142,351 Mar 04 06:12 PM Gollob Jared Chief Medical Officer Mar 04 '24 Sale 41.86 3,344 139,967 95,740 Mar 04 06:21 PM Albers Jeffrey W. Director Feb 21 '24 Option Exercise 10.34 4,385 45,341 4,385 Feb 21 06:46 PM Albers Jeffrey W. Director Feb 21 '24 Sale 39.05 4,385 171,227 0 Feb 21 06:46 PM Albers Jeffrey W. Director Feb 20 '24 Option Exercise 10.34 615 6,359 615 Feb 21 06:46 PM Albers Jeffrey W. Director Feb 20 '24 Sale 39.07 615 24,031 0 Feb 21 06:46 PM Gollob Jared Chief Medical Officer Feb 09 '24 Option Exercise 2.08 46,137 95,965 120,846 Feb 09 07:47 PM Gollob Jared Chief Medical Officer Feb 09 '24 Sale 35.50 46,137 1,638,071 74,709 Feb 09 07:47 PM Albers Jeffrey W. Director Jan 23 '24 Option Exercise 10.34 10,000 103,400 10,000 Jan 23 07:37 PM Albers Jeffrey W. Director Jan 23 '24 Sale 30.05 10,000 300,470 0 Jan 23 07:37 PM Chiniara Ellen Chief Legal Officer Jan 04 '24 Sale 22.58 3,295 74,416 34,205 Jan 05 05:15 PM Mainolfi Nello Chief Executive Officer Jan 02 '24 Option Exercise 2.08 9,000 18,720 615,570 Jan 02 05:43 PM Mainolfi Nello Chief Executive Officer Nov 03 '23 Option Exercise 2.08 20,000 41,600 606,570 Nov 06 06:00 PM BVF PARTNERS L P/IL Director Nov 03 '23 Buy 14.07 197,699 2,781,407 2,656,191 Nov 06 06:07 PM BVF PARTNERS L P/IL Director Nov 02 '23 Buy 11.64 216,406 2,519,918 2,552,306 Nov 06 06:07 PM Mainolfi Nello Chief Executive Officer Aug 08 '23 Option Exercise 2.08 12,000 24,960 586,570 Aug 08 04:30 PM Jacobs Bruce N. Chief Financial Officer Jun 02 '23 Option Exercise 2.08 10,000 20,800 115,035 Jun 02 02:17 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite